International Clinics
Breaking
FDA approves venglustat, the first treatment for neurological symptoms of type 3 Gaucher disease
On 18 November 2026 the FDA approved Sanofi's Infilbray (venglustat).
On 18 November 2026 the FDA approved Sanofi's Infilbray (venglustat).
Nothing more to show